



# Increased NEFA levels reduce blood $Mg^{2+}$ in hypertriacylglycerolaemic states via direct binding of NEFA to $Mg^{2+}$

Steeff Kurstjens<sup>1</sup> · Jeroen H. F. de Baaij<sup>1,2</sup> · Caro Overmars-Bos<sup>1</sup> · Inge C. L. van den Munckhof<sup>3</sup> · Veronica Garzero<sup>1</sup> · Marijke A. de Vries<sup>4</sup> · Benjamin Burggraaf<sup>4</sup> · Janna A. van Diepen<sup>3</sup> · Niels P. Riksen<sup>3</sup> · Joost H. W. Rutten<sup>3</sup> · Mihai G. Netea<sup>3,5</sup> · Manuel Castro Cabezas<sup>4</sup> · René J. M. Bindels<sup>1</sup> · Frances M. Ashcroft<sup>2</sup> · Cees J. J. Tack<sup>3</sup> · Joost G. J. Hoenderop<sup>1</sup>

Received: 6 July 2018 / Accepted: 5 October 2018 / Published online: 13 November 2018  
© The Author(s) 2018

## Abstract

**Aims/hypothesis** The blood triacylglycerol level is one of the main determinants of blood  $Mg^{2+}$  concentration in individuals with type 2 diabetes. Hypomagnesaemia (blood  $Mg^{2+}$  concentration  $<0.7$  mmol/l) has serious consequences as it increases the risk of developing type 2 diabetes and accelerates progression of the disease. This study aimed to determine the mechanism by which triacylglycerol levels affect blood  $Mg^{2+}$  concentrations.

**Methods** Using samples from 285 overweight individuals (BMI  $>27$  kg/m<sup>2</sup>) who participated in the 300-Obesity study (an observational cross-sectional cohort study, as part of the Human Functional Genetics Projects), we investigated the association between serum  $Mg^{2+}$  with laboratory variables, including an extensive lipid profile. In a separate set of studies, hyperlipidaemia was induced in mice and in healthy humans via an oral lipid load, and blood  $Mg^{2+}$ , triacylglycerol and NEFA concentrations were measured using colourimetric assays. In vitro, NEFAs harvested from albumin were added in increasing concentrations to several  $Mg^{2+}$ -containing solutions to study the direct interaction between  $Mg^{2+}$  and NEFAs.

**Results** In the cohort of overweight individuals, serum  $Mg^{2+}$  levels were inversely correlated with triacylglycerols incorporated in large VLDL particles ( $r = -0.159$ ,  $p \leq 0.01$ ). After lipid loading, we observed a postprandial increase in plasma triacylglycerol and NEFA levels and a reciprocal reduction in blood  $Mg^{2+}$  concentration both in mice ( $\Delta$  plasma  $Mg^{2+} -0.31$  mmol/l at 4 h post oral gavage) and in healthy humans ( $\Delta$  plasma  $Mg^{2+} -0.07$  mmol/l at 6 h post lipid intake). Further, in vitro experiments revealed that the decrease in plasma  $Mg^{2+}$  may be explained by direct binding of  $Mg^{2+}$  to NEFAs. Moreover,  $Mg^{2+}$  was found to bind to albumin in a NEFA-dependent manner, evidenced by the fact that  $Mg^{2+}$  did not bind to fatty-acid-free albumin. The NEFA-dependent reduction in the free  $Mg^{2+}$  concentration was not affected by the presence of physiological concentrations of other cations.

**Conclusions/interpretation** This study shows that elevated NEFA and triacylglycerol levels directly reduce blood  $Mg^{2+}$  levels, in part explaining the high prevalence of hypomagnesaemia in metabolic disorders. We show that blood NEFA level affects the free  $Mg^{2+}$  concentration, and therefore, our data challenge how the fractional excretion of  $Mg^{2+}$  is calculated and interpreted in the clinic.

Cees J. J. Tack and Joost G. J. Hoenderop contributed equally to this work.

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00125-018-4771-3>) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Joost G. J. Hoenderop  
joost.hoenderop@radboudumc.nl

<sup>1</sup> Department of Physiology (286), Radboud Institute for Molecular Life Sciences, Radboud university medical center, P. O. Box 9101, 6500 HB Nijmegen, the Netherlands

<sup>2</sup> Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

<sup>3</sup> Department of Internal Medicine, Radboud university medical center, Nijmegen, the Netherlands

<sup>4</sup> Department of Internal Medicine, Center for Diabetes and Vascular Medicine, Franciscus Gasthuis Rotterdam, Rotterdam, the Netherlands

<sup>5</sup> Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany

## Research in context

### What is already known about this subject?

- Hypomagnesaemia is a common phenomenon in individuals with type 2 diabetes
- Triacylglycerols are a major determinant of changes in blood  $Mg^{2+}$  concentrations
- Reduced  $Mg^{2+}$  levels increase the risk of developing type 2 diabetes and escalate progression of the disease

### What is the key question?

- How do triacylglycerols and NEFAs affect  $Mg^{2+}$  homeostasis?

### What are the new findings?

- $Mg^{2+}$  levels inversely correlate with triacylglycerols in large VLDL particles in overweight individuals
- Elevating triacylglycerol and NEFA levels directly reduces  $Mg^{2+}$  concentrations in mice and healthy individuals, unravelling the directionality of the inverse correlation
- NEFAs directly bind to  $Mg^{2+}$ , thereby reducing ionised  $Mg^{2+}$  levels

### How might this impact on clinical practice in the foreseeable future?

- The findings from this study may explain why factors and medication that induce high NEFA levels (e.g.  $\beta$ -adrenergic agonists, ethanol, adrenaline and fasting) are associated with hypomagnesaemia. This is especially important when managing hypertriacylglycerolaemic individuals with diabetes, who are at a particular risk of hypomagnesaemia

**Keywords** Albumin · Hypertriacylglycerolaemia · Hypomagnesaemia · Magnesium · Magnesium deficiency · Non-esterified fatty acid · Obesity · Triacylglycerols

## Abbreviations

FF-BSA	Fatty-acid-free BSA
FEMg	Fractional excretion of $Mg^{2+}$
ICP-MS	Inductively coupled plasma mass spectrometry
NMR	Nuclear magnetic resonance

## Introduction

Hypomagnesaemia (blood  $Mg^{2+}$  concentration  $<0.7$  mmol/l) is commonly observed in individuals with type 2 diabetes or the metabolic syndrome [1–3] and can result in general complaints such as fatigue, headache and weakness [4, 5]. Low oral  $Mg^{2+}$  intake and low blood  $Mg^{2+}$  levels not only increase the risk of developing type 2 diabetes but also accelerate disease progression [6–8]. A reduced blood  $Mg^{2+}$  is also associated with diabetes-related complications, such as cardiovascular disease and renal failure [9–12].

Blood  $Mg^{2+}$  levels are carefully maintained between 0.7 and 1.1 mmol/l by the interplay between intestine, bone and kidney [13]. In blood, approximately 27% of  $Mg^{2+}$  is bound to albumin and 8% is complexed to anions, such as phosphate, bicarbonate and citrate, leaving 65% as the free, biologically active form [14]. Although the phenomenon of albumin binding to  $Mg^{2+}$  has been known for decades, investigations into

the buffering effect of albumin on the regulation of  $Mg^{2+}$  homeostasis has been largely neglected [15].

Blood fatty acid and triacylglycerol levels are largely regulated by four organs: the intestine, liver, muscle and adipose tissue. In the postprandial state, the intestine absorbs dietary lipids as fatty acids, which are re-esterified into triacylglycerols and incorporated into chylomicrons that reach metabolically active tissues via the circulation [16]. The liver can also incorporate fatty acids into triacylglycerol and secrete these as VLDL particles; this process is especially important during fasting [17]. Skeletal muscle stores fatty acids in the form of triacylglycerols but also consumes large amounts of fatty acids during exercise [18]. White adipose tissue also stores fatty acids as triacylglycerols, which can be released by lipolysis as NEFAs during a state of energy deprivation [19, 20]. In the blood, these negatively charged NEFAs are bound to carrier proteins, predominantly albumin, via non-polar interactions [21]. In physiological conditions, approximately two NEFA molecules are bound to a single albumin molecule [22]. However, in a state of hypertriacylglycerolaemia, up to seven NEFA molecules are able to bind to albumin, albeit with sequentially lower binding constants [21, 22].

In metabolic diseases, high blood triacylglycerol concentrations are associated with a lower blood  $Mg^{2+}$  concentration, but the directionality of this correlation remains unclear [1, 23, 24]. Severe hypomagnesaemia in animals leads to increased

blood triacylglycerol levels, possibly by disrupting the function of the enzyme lecithin-cholesterol acyltransferase or by activating lipolysis in adipose tissue [25, 26]. However, whether triacylglycerols can affect  $Mg^{2+}$  homeostasis has not yet been investigated.

In this study, we measured serum  $Mg^{2+}$  concentrations and plasma lipoprotein concentrations and composition in a cohort of overweight individuals, by use of a metabolomics platform [27]. To further unravel the exact relationship between hypertriacylglycerolaemia and  $Mg^{2+}$  levels, we combined a population-based cross-sectional study with *in vivo* oral lipid loading in both humans and mice, and carried out subsequent investigations *in vitro*.

## Methods

**300-Obesity cohort** Three hundred and two individuals, aged 55–80 years, were enrolled in the 300-Obesity cohort study (an observational cross-sectional cohort study within the Human Functional Genetics Projects) at the Radboud university medical center between 2014 and 2016 [28]. The study was carried out in accordance with the Declaration of Helsinki and all participants provided informed consent. All participants had a BMI above  $27 \text{ kg/m}^2$ . Individuals with a recent cardiovascular event (myocardial infarction, transient ischaemic attack, stroke <6 months ago), a history of bariatric surgery or bowel resection, inflammatory bowel disease, renal dysfunction or increased bleeding tendency, or who used oral or subcutaneous anticoagulant therapy or thrombocyte aggregation inhibitors (other than acetylsalicylic acid and carbasalate calcium) were excluded. Blood samples were taken in the morning, following an overnight fast. Blood glucose, triacylglycerols, total cholesterol and HDL-cholesterol were measured using standard laboratory procedures (Cobas C8000; Roche Diagnostics, Risch-Rotkreuz, Switzerland). The HOMA-IR was calculated using the standard formula, as published by Matthews et al [29]. High-throughput nuclear magnetic resonance (NMR) metabolomics platform (Nightingale's Biomarker Analysis Platform, Nightingale Health, Helsinki, Finland) [27] was used for the quantification of 231 lipid and metabolite measures. The metabolites were measured in a single experiment, set-up for the quantification of different metabolite groups. In this article we focus on lipoproteins: total lipid concentrations of 14 lipoprotein subclasses, lipoprotein particles sizes, apolipoproteins and cholesterol. The NMR metabolomics platform used in this study has previously been used in various epidemiological studies [30, 31]. Details of the NMR-based metabolomics experimentation have been described previously [27]. In the present study, serum  $Mg^{2+}$  levels were measured in all individuals. However, 17 measurements had substantial duplo errors (large deviations  $\geq 0.05 \text{ mmol/l}$  from the average) between duplicate

measurements) and, therefore, only 285 individuals were included in the analysis.

**Oral gavage of olive oil in wild-type mice** This animal study was approved by the animal ethics board of the Radboud University Nijmegen (RU DEC 2015-0073) and by the Dutch Central Commission for Animal Experiments (CCD, AVD103002015239). Twelve male C57BL6/J mice (Charles River, Sulzfeld, Germany) were obtained at an age of 9–10 weeks. Mice were acclimatised for 2 weeks in a temperature- and light-controlled room, with six mice per cage (Eurostandard Type III, Tecniplast, Buguggiate, Italy), and were allowed free access to acidified tap water and standard pellet chow (Ssniff Spezialdiäten, Soest, Germany). After the acclimatisation period, mice received experimental chow containing 18.3% protein (wt/wt), 4.1% crude fat (wt/wt), 25.1% starch (wt/wt) and 33.6% sugar (wt/wt) (E15000-04; Ssniff Spezialdiäten). After 2 weeks on the synthetic diet, mice were fasted overnight, from 21:00 to 09:00 hours, before receiving 200  $\mu\text{l}$  intragastric olive oil (extra virgin; Carbonell, Cordoba, Spain) via oral gavage. Blood was drawn via tail-bleed, using chilled sodium-heparin capillary tubes (Praxisdienst, Longuich, Germany) coated with paraoxon (Sigma, St Louis, MO, USA), before the gavage (0 h) and at 1, 2, 4, 6 and 8 h post gavage. The blood was centrifuged at 3000 g and plasma was procured.

**Oral gavage of olive oil in a mouse model of diabetes** All procedures for this experiment were conducted in compliance with the UK Animals Scientific Procedures Act (1986) and University of Oxford ethical guidelines. Kir6.2-p.Val59Met mice were generated in our laboratories, as previously published [32]. All mice were 12–16 weeks old. Mice were housed with a maximum of five animals per cage (ventilated), separated by gender and with *ad libitum* access to food and standard pellet chow, in a 12 h light/dark cycle, at  $21^\circ\text{C}$ . In four male and four female C57BL6 mice, expression of a Kir6.2-p.Val59Met transgene was induced using subcutaneous injection of 400  $\mu\text{l}$  tamoxifen (0.02 g/ml corn oil). This inducible mouse model recapitulates the phenotype of neonatal diabetes and these mice develop diabetes due to impaired insulin secretion [32, 33].

Three days after tamoxifen injection, mice were fasted overnight from 17:00 to 09:00 hours. Successful induction of the Kir6.2-p.Val59Met transgene was validated by measuring fasted blood glucose levels using a StatStrip Xpress glucose meter (Nova Biomedical, Waltham, MA, USA). One female mouse did not have elevated fasting glucose levels and was excluded from subsequent analyses. The remaining mice then underwent oral gavage and blood sampling using an identical experimental set up to that described above for C57BL6/J wild-type mice.

**BSA and fatty-acid-free BSA solutions** BSA and fatty-acid-free BSA (FF-BSA) (both Sigma Aldrich) were separately

dissolved at several concentrations in a 1 mmol/l  $\text{MgCl}_2$  solution (Merck Millipore, Darmstadt, Germany) or a physiological buffer, both set at pH 7.5 by adding NaOH. The physiological buffer contained the following (all from Merck Millipore unless stated otherwise): 27 mmol/l  $\text{NaHCO}_3$ , 112 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l  $\text{MgCl}_2$ , 1 mmol/l  $\text{Na}_2\text{HPO}_4$  (VWR International, Radnor, PA, USA) and 2.5 mmol/l  $\text{CaCl}_2$  dissolved in Milli-Q (Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands).

**Increasing NEFA levels in BSA, FBS and  $\text{MgCl}_2$  solutions** To extract endogenous NEFAs, BSA (0.2 g/ml) dissolved in Milli-Q was mixed (1:2 vol./vol.) with ice-cold ethanol–diethyl ether (3:1 vol./vol.). The lipid phase was evaporated overnight at room temperature. To remove trace amounts of BSA, the solution was centrifuged three times with an Amicon 50 kDa filter (Merck Millipore) for 15 min at 2500 g to clog the protein in the filter. Extracted NEFAs were added to 250  $\mu\text{l}$  FBS (Biowest, Nuaille, France), 1 mmol/l  $\text{MgCl}_2$ , or 0.5 mmol/l BSA in the amounts of 0, 25, 50, 100, 200, 350, 500 and 700  $\mu\text{l}$ . Dilution factors were accounted for when measuring the concentrations of  $\text{Mg}^{2+}$  and NEFA.

**Analytical measurements** Protein (Pierce, Thermo Scientific, Waltham, MA, USA), NEFA (WAKO Diagnostics, Delfzijl, the Netherlands), triacylglycerols (Roche Molecular Biochemicals, Indianapolis, IN, USA) and  $\text{Mg}^{2+}$  (Roche/Hitachi, Tokyo, Japan) concentrations were measured using a spectrophotometric assay according to the manufacturer's protocols. The  $\text{Mg}^{2+}$  colourimetric assay was based on a Xylidyl Blue-I method and the absorbance was measured at 600 nm. NEFAs were measured at 546 nm, triacylglycerols at 500 nm and protein at 562 nm on a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad laboratories, Hercules, CA, USA). For inductively coupled plasma mass spectrometry (ICP-MS) analyses, serum samples were dissolved in  $\text{HNO}_3$  (>65%, Sigma) and diluted prior to being subjected to ICP-MS (X-series; Thermo Scientific).

**Oral lipid load in human participants** As part of a study ([ClinicalTrials.gov](https://clinicaltrials.gov) registration no. NCT01967459), which aimed to examine the effect of vitamin D supplementation on postprandial leucocyte activation, 24 female volunteers underwent an oral fat-loading test. The study was approved by the Institutional Review Board of the Franciscus Gasthuis & Vlietland Rotterdam and the regional independent medical ethics committee of the Maasstad Hospital Rotterdam [34]. All participants provided informed consent. Samples from the baseline oral fat load were used in this study to measure serum  $\text{Mg}^{2+}$ , NEFA and triacylglycerol concentrations.

Inclusion criteria were an age above 18 years, a premenopausal status,  $\text{BMI} \geq 25 \text{ kg/m}^2$  and vitamin D deficiency. Exclusion criteria were the use of any kind of medication

(except for oral contraceptives), smoking, pregnancy, participation in a clinical study less than 6 months before inclusion and the use of vitamin supplements.

Participants visited the hospital after a 10 h overnight fast and venous blood samples were obtained after an oral fat load (before Vitamin D treatment). Each participant received an oral fat load using fresh cream (Albert Heijn, Zaandam, the Netherlands) at a dose of 50 g of fat per  $\text{m}^2$  body surface calculated by the Mosteller formula [35]. During the oral fat loading, test participants were not allowed to eat or to drink (except water) and they were asked to refrain from physical activity. Venous blood sampling was repeated at 2 h intervals until 8 h after oral fat loading, and serum  $\text{Mg}^{2+}$  and NEFA levels and plasma triacylglycerol levels were measured (as detailed in the 'Analytical measurements' section above). Two individuals were excluded due to insufficient sample availability.

**Statistical analyses** Results are presented as mean  $\pm$  SEM, unless stated otherwise. Variables of overweight individuals were correlated univariately to serum  $\text{Mg}^{2+}$  levels using Pearson's correlation analyses (SPSS for Windows v22.0.0.1, RRID:SCR\_002865; IBM, New York, NY, USA). Based on the initial experiment in wild-type mice, the sample size for the experiment in Kir6.2-p.Val59Met mice was calculated using a one-way ANOVA statistic (with Dunnett's correction for multiple comparison); to detect an effect size of 0.3 (SD 0.13) with a power of 80% and  $\alpha$  level of 5%: a total of six mice were required per group. The sample size of the oral lipid (cream) load study in healthy individuals was assessed using a one-way ANOVA (with Dunnett's correction for multiple comparison); to detect an effect size of 0.1 (SD 0.1) with a power of 80% and an  $\alpha$  level of 5%: a total of 23 individuals were required. Significance of  $\text{Mg}^{2+}$ , triacylglycerol and NEFA concentrations at 1, 2, 4, 6 and 8 h compared with those at 0 h was evaluated using a one-way ANOVA with Dunnett's correction for multiple comparisons. Direct correlations between  $\text{Mg}^{2+}$  and triacylglycerol or NEFA concentrations were assessed using linear regression analyses. A  $p$  value of  $\leq 0.05$  was considered statistically significant. All statistical analyses were performed using Graphpad Prism v7 (RRID:SCR\_002798; Graphpad software, La Jolla, CA, USA).

## Results

**Serum  $\text{Mg}^{2+}$  levels inversely correlate with blood triacylglycerol levels in overweight individuals** Factors affecting blood  $\text{Mg}^{2+}$  levels were evaluated in 285 overweight individuals ( $\text{BMI} > 27 \text{ kg/m}^2$ ) from the 300-Obesity cohort (ESM Table 1). The mean serum  $\text{Mg}^{2+}$  concentration in this cohort was  $0.89 \pm 0.09$  (SD) mmol/l, with only 2% of the individuals having hypomagnesaemia (serum  $\text{Mg}^{2+} < 0.7$  mmol/l, see

ESM Table 1 and ESM Fig. 1). Despite the fairly healthy serum  $Mg^{2+}$  levels in these individuals, serum  $Mg^{2+}$  concentrations were inversely correlated with triacylglycerol levels, predominantly those in VLDL particles (Table 1). The serum  $Mg^{2+}$  concentration was also inversely correlated with HOMA-IR. As HOMA-IR was strongly correlated with plasma triacylglycerol concentration (ESM Tables 2, 3), we questioned whether insulin resistance modulated the inverse correlation between serum  $Mg^{2+}$  and plasma triacylglycerol levels and triacylglycerols in VLDL particles. However, HOMA-IR did not influence these correlations in multivariable regression analyses (ESM Tables 4 and 5).

To further investigate the relationship between lipoproteins and serum  $Mg^{2+}$  level, the composition of lipoprotein particles was investigated and the correlation of these particles with serum  $Mg^{2+}$  concentration was analysed (Table 1). The concentration of the larger VLDL particles showed the strongest inverse correlations with serum  $Mg^{2+}$  levels (Table 1). Interestingly, the concentration of smaller HDL particles was positively correlated with serum  $Mg^{2+}$ . There was no correlation between serum  $Mg^{2+}$  levels and the concentration of any of the intermediate-density lipoprotein and LDL particles (Table 1). No significant correlation was observed between serum  $Mg^{2+}$  and the diameter of the VLDL, LDL or HDL particles (Table 1).

**Increased triacylglycerol levels directly reduce plasma  $Mg^{2+}$  concentrations in mice** To unravel the underlying mechanism that explains how blood triacylglycerols are associated with blood  $Mg^{2+}$  concentrations, mice were subjected to an oral gavage of olive oil following an overnight fast. Plasma triacylglycerols and NEFA levels both peaked at 4 h post-gavage (Fig. 1a, b,  $\Delta$  plasma  $Mg^{2+}$   $-0.31$  mmol/l at 4 h post-gavage). Interestingly, the plasma  $Mg^{2+}$  concentration showed a reciprocal decrease, reaching a nadir at 4 h post-gavage (Fig. 1a, b). At basal levels (0 h), no significant correlation was observed between plasma  $Mg^{2+}$  levels and NEFA concentrations (Fig. 1c,  $p = 0.27$ ). However, when plasma NEFA levels increased (at 4 and 6 h), there was a clear inverse correlation between plasma  $Mg^{2+}$  and NEFA concentrations (Fig. 1d, e,  $p \leq 0.05$ ). When plasma NEFA levels decreased and reached a concentration approaching levels at baseline (8 h), there was no longer a significant correlation between plasma NEFA and  $Mg^{2+}$  concentrations (Fig. 1f,  $p = 0.54$ ). Similar correlations were observed between plasma  $Mg^{2+}$  and triacylglycerol levels (ESM Fig. 2a–d).

Increased blood lipids can enhance glucose-induced insulin secretion [36]. Insulin induces a compartmental shift of  $Mg^{2+}$ , decreasing the blood concentration of  $Mg^{2+}$  and increasing intracellular levels [37]. Hence, to rule out insulin-dependent effects, the same oral gavage experiment was performed in inducible Kir6.2-p.Val59Met mice, which develop hypoinsulinaemia and hyperglycaemia [38]. In these mice, a similar reduction in plasma  $Mg^{2+}$  was observed in response to

the oral gavage of olive oil as compared with wild-type mice (Fig. 1g). However, while the reduction in the plasma  $Mg^{2+}$  concentration was numerically similar to that observed in wild-type mice, it did not reach statistical significance in Kir6.2-p.Val59Met mice due to a high variation between the animals (which was substantially larger than in the initial experiment using wild-type mice). However, a significant inverse correlation between plasma  $Mg^{2+}$  and triacylglycerols was still observed in these hypoinsulinaemic mice (Fig. 1h,  $p \leq 0.05$ ).

**Binding of  $Mg^{2+}$  to albumin is NEFA-dependent** As ~30% of  $Mg^{2+}$  is bound to albumin, which is the predominant carrier of NEFAs, we investigated whether the binding of  $Mg^{2+}$  to albumin is dependent on NEFAs [14]. With increasing concentrations of BSA in  $MgCl_2$ , we found that the  $Mg^{2+}$  concentration declined as BSA concentrations increased (Fig. 2a).  $Mg^{2+}$  concentrations decreased from  $0.85 \pm 0.02$  mmol/l at 0 mmol/l BSA to  $0.64 \pm 0.01$  mmol/l at a near-physiological concentration of BSA (0.5 mmol/l or 33.25 g/l), a 25% reduction (Fig. 2a). Interestingly, the absence of fatty acid (i.e. the use of FF-BSA instead of BSA in the  $MgCl_2$  solution) abrogated this effect, in line with the theory that binding of  $Mg^{2+}$  to albumin is NEFA-dependent (Fig. 2b). Linear regression analyses showed a significant inverse correlation between  $Mg^{2+}$  and BSA concentration (Fig. 2c); the regression constant was approximately four times stronger for BSA than for FF-BSA (Fig. 2c). To exclude the possibility that other cations present in blood compete with the binding of  $Mg^{2+}$  to BSA, BSA was also dissolved in a physiological buffer, which mimicked the concentration of other abundant blood electrolytes. This approach resulted in a similar decrease in the  $Mg^{2+}$  concentration with increasing BSA concentrations (Fig. 2d). Again, FF-BSA had no significant effect on  $Mg^{2+}$  levels (Fig. 2e). In the physiological buffer, BSA and FF-BSA displayed correlations similar to those observed in the  $MgCl_2$  buffer (Fig. 2f).

**NEFAs directly decrease  $Mg^{2+}$  concentrations** We then set out to modify the binding of  $Mg^{2+}$  to albumin by increasing the concentration of NEFA. Elevating the concentration of NEFAs in a BSA– $MgCl_2$  solution directly reduced the  $Mg^{2+}$  concentration (linear regression:  $y = -0.12x + 0.83$ ,  $p \leq 0.05$ ; Fig. 3a). To resemble the in vivo setting, the experiment was repeated using FBS instead of BSA; increasing NEFA levels in FBS reduced  $Mg^{2+}$  concentrations to a similar extent as when BSA was used (linear regression:  $y = -0.10x + 1.36$ ,  $p \leq 0.05$ ; Fig. 3b). Interestingly, the NEFA-induced reduction in  $Mg^{2+}$  concentration was protein-independent, as increasing NEFA levels in a  $MgCl_2$  solution also lowered  $Mg^{2+}$  concentration (linear regression:  $y = -0.08x + 1.00$ ,  $p \leq 0.05$ ; Fig. 3c).


**Elevating triacylglycerol levels reduces serum  $Mg^{2+}$  concentration in healthy individuals** To discover whether

**Table 1** Univariate analyses for the correlation of demographics, laboratory measurements and lipoprotein particle concentration with serum Mg<sup>2+</sup> concentration in overweight individuals from the 300-Obesity cohort

Variable	Correlation coefficient	<i>p</i> value	<i>n</i>
<b>Demographics</b>			
Sex (M = 0, F = 1)	−0.051	0.391	285
BMI (kg/m <sup>2</sup> )	−0.063	0.291	285
Age (years)	−0.099	0.096	285
Waist circumference (cm)	−0.071	0.231	285
SBP (mmHg)	−0.016	0.791	285
DBP (mmHg)	0.079	0.186	285
Heart rate (beats/min)	−0.083	0.164	282
<b>Laboratory measures</b>			
Triacylglycerols (mmol/l)	−0.159	0.007	284
Glucose (mmol/l)	−0.062	0.299	284
HbA <sub>1c</sub> (mmol/mol)	−0.032	0.595	284
HOMA-IR	−0.123	0.038	283
Total cholesterol (mmol/l)	0.041	0.495	284
<b>Triacylglycerols (mmol/l)</b>			
in VLDL	−0.158	0.008	284
in LDL	−0.026	0.667	284
in HDL	−0.052	0.380	284
<b>Cholesterol (mmol/l)</b>			
in VLDL	−0.093	0.118	284
in LDL	0.075	0.205	284
HDL	0.116	0.050	284
ApoA1 (g/l)	0.071	0.235	283
ApoB (g/l)	−0.037	0.539	283
<b>Mean lipoprotein diameter (nm)</b>			
VLDL	−0.095	0.111	284
LDL	−0.030	0.612	284
HDL	0.026	0.320	284
<b>Lipoprotein particle concentration (mol/l)</b>			
Chylomicrons and EL-VLDL	−0.170	0.004	284
VL-VLDL	−0.174	0.003	284
L-VLDL	−0.163	0.006	284
M-VLDL	−0.149	0.012	284
S-VLDL	−0.108	0.068	284
VS-VLDL	−0.004	0.942	284
IDL	0.058	0.333	284
L-LDL	0.060	0.313	284
M-LDL	0.059	0.319	284
S-LDL	0.053	0.377	284
VL-HDL	0.020	0.739	284
L-HDL	0.089	0.137	284
M-HDL	0.163	0.006	284
S-HDL	0.179	0.002	284

ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; DBP, diastolic blood pressure; EL-VLDL, extra-large VLDL; F, female; IDL, intermediate-density lipoprotein; L-HDL, large HDL; L-LDL, large LDL; L-VLDL, large VLDL; M, male; M-HDL, medium HDL; M-LDL, medium LDL; M-VLDL, medium VLDL; SBP, systolic blood pressure; S-HDL, small HDL; S-LDL, small LDL; S-VLDL, small VLDL; VL-HDL, very large HDL; VL-VLDL, very large VLDL; VS-VLDL, very small VLDL

**Fig. 1** Increased plasma NEFA and triacylglycerol levels directly reduce plasma  $Mg^{2+}$  concentration in mice. Mice were given an oral gavage of 200  $\mu$ l olive oil. **(a)** Plasma  $Mg^{2+}$  (red circles) and triacylglycerol (blue squares) and **(b)** plasma  $Mg^{2+}$  (red circles,) and NEFA (blue squares) concentrations before (0 h) and at 1, 2, 4, 6 and 8 h post-gavage in wild-type mice ( $n = 12$ ). **(c–f)** Linear regression analyses of plasma  $Mg^{2+}$  and NEFA concentrations at 0 h (**c**,  $n = 8$ ), 4 h (**d**,  $n = 12$ ), 6 h (**e**,  $n = 12$ ) and 8 h (**f**,  $n = 11$ ) post gavage in wild-type mice, using data from **(b)**. Each point represents an individual mouse; several data points are missing due to insufficient sample availability. **(g)** Plasma  $Mg^{2+}$  (red circles) and triacylglycerol (blue squares) concentrations before (0 h) and at 1, 2, 4, 6 and 8 h post-gavage in hypoinsulinaemic Kir6.2-p.Val59Met mice ( $n = 7$ ). **(h)** Linear regression analysis of plasma  $Mg^{2+}$  and triacylglycerol concentration at 4 h post-gavage, using data shown in **(g)**. Each point represents an individual mouse;  $n = 2$  mice were excluded due to insufficient sample availability. Data are mean  $\pm$  SEM. \* $p \leq 0.05$ , \*\*\* $p \leq 0.001$  vs  $Mg^{2+}$  concentrations at 0 h; † $p \leq 0.05$ , †† $p \leq 0.01$ , ††† $p \leq 0.001$  vs triacylglycerol or NEFA concentrations at 0 h. Significance was evaluated using a one-way ANOVA with Dunnett's correction for multiple comparisons




triacylglycerols and NEFAs also affect blood  $Mg^{2+}$  concentration in humans, we examined samples obtained from 24 healthy female individuals, with a BMI  $>25$  kg/m<sup>2</sup>, who received an oral fat load [34]. Serum NEFA and  $Mg^{2+}$  levels and plasma triacylglycerol concentrations were measured over a period of 8 h. Plasma triacylglycerol levels increased significantly, from  $1.18 \pm 0.10$  mmol/l at 0 h to a peak of  $2.13 \pm 0.18$  mmol/l at 4 h (Fig. 4a). Serum NEFA concentrations also significantly increased, from  $0.38 \pm 0.03$  mmol/l at 0 h to a peak of  $0.76 \pm 0.04$  mmol/l at 6 h (Fig. 4b). In accordance with our previous findings, serum  $Mg^{2+}$  levels dropped from  $0.82 \pm 0.01$  mmol/l at 0 h to a nadir of  $0.75 \pm 0.02$  mmol/l at 6 h (Fig. 4a, b,  $\Delta$  plasma  $Mg^{2+} -0.07$  mmol/l at 6 h post-intake). The total serum

$Mg^{2+}$  concentration, as measured by ICP-MS, was not affected by fat (cream) intake; hence, these findings suggest that only the free  $Mg^{2+}$  levels were affected by lipid loading (Fig. 4c).

## Discussion

Hypomagnesaemia is a common phenomenon in type 2 diabetes. In the current study, we show that high blood NEFA and triacylglycerol concentrations directly reduce blood  $Mg^{2+}$  levels. We also show that high NEFA levels bind  $Mg^{2+}$ , resulting in decreased circulating levels of free  $Mg^{2+}$ . The conclusions of this study are based on complementary results from




**Fig. 2** Binding of  $Mg^{2+}$  to albumin is NEFA-dependent. **(a, b)** The  $Mg^{2+}$  concentration in an increasing level of BSA **(a)** or FF-BSA **(b)** dissolved in a  $MgCl_2$  solution. The white squares indicate a BSA/FF-BSA concentration (0.5 mmol/l) that is near the physiological range; all other data points are shown in grey. **(c)** Linear regression analyses of the  $Mg^{2+}$  concentration in increasing levels of BSA (circles;  $y = -0.21x + 0.78$ ,  $r^2 = 0.96$ ,  $p \leq 0.05$ ) or FF-BSA (triangles;  $y = -0.05x + 0.83$ ,  $r^2 = 0.90$ ,  $p \leq 0.05$ ), using data shown in **(a)** and **(b)**. **(d, e)** The  $Mg^{2+}$  concentration in an increasing level of BSA **(d)** or FF-BSA **(e)** dissolved in a physiological buffer. The white squares indicate a BSA/FF-BSA concentration

(0.5 mmol/l) that is near the physiological range; all other data points are shown in grey. **(f)** Linear regression analyses of the  $Mg^{2+}$  concentration in increasing levels of BSA (circles;  $y = -0.21x + 0.78$ ,  $r^2 = 0.96$ ,  $p \leq 0.05$ ) or FF-BSA (triangles;  $y = -0.05x + 0.83$ ,  $r^2 = 0.90$ ,  $p \leq 0.05$ ), using data shown in **(d)** and **(e)**. Data are mean  $\pm$  SEM of three replicate experiments. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$  vs  $Mg^{2+}$  concentrations in 0.5 mmol/l BSA/FF-BSA. Significance was evaluated using a one-way ANOVA with Dunnett's correction for multiple comparisons **(a, b, d, e)** or using a linear regression analysis **(c, f)**

in vitro studies and animal and human in vivo studies. First, in a large cohort of overweight individuals, the concentration of triacylglycerols in large VLDL particles was inversely correlated with serum  $Mg^{2+}$  concentrations. Second, a dietary lipid load directly reduced blood  $Mg^{2+}$  concentration in both mice and humans, independent of insulin action. Third, in vitro, we demonstrated that this phenomenon occurs due to direct binding of NEFA molecules to  $Mg^{2+}$ . These findings demonstrate that

triacylglycerols reduce concentrations of free  $Mg^{2+}$  in the blood and consequently place hypertriacylglycerolaemic individuals at risk for  $Mg^{2+}$  deficiency.


Here, we demonstrated that increased triacylglycerol and NEFA levels reduce levels of free  $Mg^{2+}$  (the biologically active form of  $Mg^{2+}$ ) by a direct interaction between negatively charged NEFA molecules and  $Mg^{2+}$  ions. This binding was shown to be highly specific for  $Mg^{2+}$ , since the presence of



**Fig. 3** NEFAs directly reduce  $Mg^{2+}$  concentrations. Linear regression analyses of  $Mg^{2+}$  and NEFA concentration in **(a)** BSA dissolved in 1 mmol/l  $MgCl_2$  ( $y = -0.12x + 0.83$ ,  $r^2 = 0.97$ ,  $p \leq 0.05$ ), **(b)** FBS ( $y = -0.10x + 1.36$ ,  $r^2 = 0.90$ ,  $p \leq 0.05$ ) and **(c)**  $MgCl_2$  solution ( $y = -0.08x +$

$1.00$ ,  $r^2 = 0.99$ ,  $p \leq 0.05$ ). Results from one representative experiment are shown. The experiment was repeated three additional times with similar results





**Fig. 4** Increased serum NEFA and plasma triacylglycerol levels directly reduce serum Mg<sup>2+</sup> concentrations in healthy overweight or obese women. Female volunteers underwent an oral fat (cream) loading test. **(a)** Serum Mg<sup>2+</sup> (red circles) and plasma triacylglycerol (blue squares) and **(b)** serum Mg<sup>2+</sup> (red circles) and NEFA (blue squares) concentrations before (0 h) and at 1, 2, 4, 6 and 8 h after an oral lipid load in healthy overweight women ( $n = 22$ ). **(c)** Total serum Mg<sup>2+</sup> levels measured by ICP-MS before (0 h) and 4 and 8 h after oral lipid intake. Data are mean  $\pm$  SEM. \* $p \leq 0.05$  vs Mg<sup>2+</sup> concentrations at 0 h; † $p \leq 0.05$ , †† $p \leq 0.01$ , ††† $p \leq 0.001$  vs triacylglycerol or NEFA concentrations at 0 h. Significance was evaluated using a one-way ANOVA with Dunnett's correction for multiple comparisons

physiological concentrations of other cations did not affect the interaction between Mg<sup>2+</sup> and NEFAs. The phenomenon of reduced Mg<sup>2+</sup> levels as a result of elevated NEFA levels has previously been observed in dogs, although no underlying mechanism was suggested [39]. In addition, previous studies have shown that Ca<sup>2+</sup> can bind to NEFAs, and that blood Ca<sup>2+</sup> concentrations are reduced by increasing NEFA levels in individuals [40]. However, in our in vitro experiments, the addition of physiological concentrations of Ca<sup>2+</sup> did not affect

the Mg<sup>2+</sup>–NEFA interaction, indicating a higher affinity of Mg<sup>2+</sup> compared with Ca<sup>2+</sup> for binding to NEFAs. This is likely due to the fact that the Mg<sup>2+</sup> ion has a significantly higher charge density than the Ca<sup>2+</sup> ion [41].

The findings from this study may explain why certain factors that affect circulating NEFAs are associated with changes in blood Mg<sup>2+</sup> concentrations. For example, molecules such as  $\beta$ -adrenergic agonists, ethanol and adrenaline (epinephrine), which activate lipolysis and, hence, increase blood NEFA levels, are associated with reduced blood Mg<sup>2+</sup> levels [1, 42–44]. Indeed, an intravenous infusion of the  $\beta$ -adrenergic agonist terbutaline causes a reduction in serum Mg<sup>2+</sup> concentration, which is correlated to the elevated concentrations of plasma NEFAs, but not glucose [45]. Although, this does not exclude the possibility of additional potential mechanisms for Mg<sup>2+</sup> decrease with use of these agents. In addition, prolonged fasting, which induces lipolysis and increases circulating NEFAs, also results in hypomagnesaemia [46].

Approximately 30% of blood Mg<sup>2+</sup> is bound to albumin [14]. However, our data indicate that the binding of Mg<sup>2+</sup> to albumin depends on the availability of NEFA. Our findings suggest that direct binding of Mg<sup>2+</sup> to albumin is minimal, since NEFA-depleted albumin showed little binding to Mg<sup>2+</sup>. To correct for albumin binding, a factor of 0.7 is used when calculating the fractional excretion of Mg<sup>2+</sup> (FEMg):  $FEMg = [(uMg \times sCr)/(sMg \times uCr \times 0.7)] \times 100$ , where sMg and uMg are the serum and urinary Mg<sup>2+</sup> levels, respectively, and sCr and uCr are the serum and urinary creatinine levels, respectively [47]. As the large majority of NEFAs in blood are bound to albumin, alterations in NEFA concentrations may be the determining factor in the binding of Mg<sup>2+</sup> to albumin [22]. This paradigm change questions the current protocol for calculating FEMg. The use of the factor of ‘0.7’ is accurate in physiological conditions but will lead to inaccurate calculations in pathological conditions such as hypertriacylglycerolaemia.

Several limitations need to be considered with regard to this study. Hypertriacylglycerolaemia in mice was achieved using olive oil, while in human volunteers this was done by an oral load of cream. Olive oil contains no Mg<sup>2+</sup>, while the cream used in the human study contains 3.3 mmol/l Mg<sup>2+</sup>, leading to a potential underestimation of the reduction in serum Mg<sup>2+</sup> in the healthy volunteers. Moreover, in the in vitro experiments, NEFAs extracted from BSA were used to increase NEFA levels in several solutions. However, the yield of this extraction procedure was not equal in each experiment performed, making it difficult to combine data from all experiments. Despite these differences in NEFA yield, the results were similar in all four replicate experiments. Finally, in overweight individuals and in individuals with type 2 diabetes, Mg<sup>2+</sup> inversely correlates with triacylglycerols [1, 23, 24]. Our in vitro data show direct binding of Mg<sup>2+</sup> to NEFA molecules, which, in contrast to triacylglycerol molecules, possess a negative charge. It is unlikely that Mg<sup>2+</sup> binds to uncharged triacylglycerol molecules. However, in humans,

blood triacylglycerols and NEFA levels strongly correlate, meaning that most individuals with hypertriacylglycerolaemia also have elevated NEFA levels, which would underlie the inverse correlation between  $Mg^{2+}$  and triacylglycerols [48–51].

This study has several strengths. Our data extend from molecule to population and have clinical implications. Moreover, we demonstrated the directionality of the inverse association between triacylglycerols and  $Mg^{2+}$ , which could explain why hypomagnesaemia is so prominent in diseases such as type 2 diabetes. Our data do not rule out the possibility that changes in  $Mg^{2+}$  concentrations could also influence lipid levels.

In conclusion, we show that elevated blood NEFA and triacylglycerol levels directly reduce blood  $Mg^{2+}$  concentrations by the binding of  $Mg^{2+}$  ions to NEFA molecules. Our data explain the high prevalence of hypomagnesaemia in several metabolic diseases, characterised by elevated triacylglycerol levels [1–3]. In individuals with these diseases, those with hypertriacylglycerolaemia are at particular risk for hypomagnesaemia, and therefore, blood  $Mg^{2+}$  levels should be routinely measured and monitored.

**Acknowledgements** The authors thank M. Voet and A. Ruiz Llombart (Department of Physiology, Radboud university medical center, Nijmegen, the Netherlands), K. Schraa (Department of Internal Medicine, Radboud university medical center, Nijmegen, the Netherlands) and R. T. Exposito (Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK) for their superb technical support.

**Data availability** The data and materials that support the findings of this study are available from the corresponding author upon reasonable request.

**Funding** This work was supported by funding from the Radboud Institute for Molecular Life Sciences and by grants from the Netherlands Organization for Scientific Research (NWO VICI 016.130.668 to JGJH) and by an IN-CONTROL CVON grant (CVON2012-03). JHFdB is supported by grants from NWO (Rubicon 825.14.021, Veni 016.186.012), the Dutch Kidney Foundation (Kolff 14OKG17) and the Dutch Diabetes Research Foundation (2017.81.014). JAvD is supported by a grant from the NWO (NWO VENI 91616083). The oral lipid load study in humans was financed by the Research Fund Department of Internal Medicine, Franciscus Gasthuis & Vlietland. MGN is supported by a Spinoza grant of the NWO. FMA is supported by an ERC (ERC Advanced Investigatorship), The Wellcome Trust (884655, 089795) and a Royal Society Research Wolfson Merit Award.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** SK and JHFdB conceived the project, designed the experiments, performed the experiments, analysed data and wrote the manuscript. VG performed experiments, analysed data and wrote the manuscript. CO-B and JAvD provided technical assistance, analysed data and critically read the manuscript. FMA, CJJT, RJMB and JGJH conceived the project, interpreted data and wrote the manuscript. ICLvdM, NPR, MGN and JHWR performed the population-based cross-sectional study, analysed and interpreted data, and critically read the manuscript. MAdV, BB and MCC performed the in vivo human study (oral cream study), analysed and interpreted data, and critically read the manuscript. All authors read and approved the final version of the manuscript. JGJH is the guarantor of this work.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

- Kurstjens S, de Baaij JH, Bouras H, Bindels RJ, Tack CJ, Hoenderop JG (2017) Determinants of hypomagnesaemia in patients with type 2 diabetes mellitus. *Eur J Endocrinol* 176(1):11–19. <https://doi.org/10.1530/EJE-16-0517>
- Mather HM, Nisbet JA, Burton GH et al (1979) Hypomagnesaemia in diabetes. *Clin Chim Acta* 95(2):235–242. [https://doi.org/10.1016/0009-8981\(79\)90364-4](https://doi.org/10.1016/0009-8981(79)90364-4)
- Guerrero-Romero F, Bermudez-Pena C, Rodriguez-Moran M (2011) Severe hypomagnesaemia and low-grade inflammation in metabolic syndrome. *Magnes Res* 24(2):45–53. <https://doi.org/10.1684/mrh.2011.0281>
- Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT (2014) Hypomagnesaemia: a clinical perspective. *Int J Nephrol Renov Dis* 7:219–230. <https://doi.org/10.2147/IJNRD.S42054>
- Grober U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. *Nutrients* 7(9):8199–8226. <https://doi.org/10.3390/nu7095388>
- Kieboom BCT, Ligthart S, Dehghan A et al (2017) Serum magnesium and the risk of prediabetes: a population-based cohort study. *Diabetologia* 60(5):843–853. <https://doi.org/10.1007/s00125-017-4224-4>
- Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL (1999) Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. *Arch Intern Med* 159(18):2151–2159. <https://doi.org/10.1001/archinte.159.18.2151>
- Fang X, Han HD, Li M et al (2016) Dose-response relationship between dietary magnesium intake and risk of type 2 diabetes mellitus: a systematic review and meta-regression analysis of prospective cohort studies. *Nutrients* 8(11):739. <https://doi.org/10.3390/nu8110739>
- Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH (2014) Role of magnesium in cardiovascular diseases. *Cardiol Rev* 22(4):182–192. <https://doi.org/10.1097/CRD.000000000000003>
- Sakaguchi Y, Shoji T, Hayashi T et al (2012) Hypomagnesaemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. *Diabetes Care* 35(7):1591–1597. <https://doi.org/10.2337/dc12-0226>
- Van Laecke S, Marechal C, Verbeke F et al (2011) The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. *Nephrol Dial Transplant* 26(7):2362–2369. <https://doi.org/10.1093/ndt/gfq728>
- Ter Braake AD, Shanahan CM, de Baaij JHF (2017) Magnesium counteracts vascular calcification: passive interference or active modulation? *Arterioscler Thromb Vasc Biol* 37(8):1431–1445. <https://doi.org/10.1161/ATVBAHA.117.309182>
- de Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. *Physiol Rev* 95(1):1–46. <https://doi.org/10.1152/physrev.00012.2014>
- Huijgen HJ, van Ingen HE, Kok WT, Sanders GT (1996) Magnesium fractions in serum of healthy individuals and CAPD patients, measured by an ion-selective electrode and ultrafiltration. *Clin Biochem* 29(3):261–266. [https://doi.org/10.1016/0009-9120\(96\)84729-B](https://doi.org/10.1016/0009-9120(96)84729-B)

15. Kroll MH, Elin RJ (1985) Relationships between magnesium and protein concentrations in serum. *Clin Chem* 31(2):244–246
16. Hussain MM (2000) A proposed model for the assembly of chylomicrons. *Atherosclerosis* 148(1):1–15. [https://doi.org/10.1016/S0021-9150\(99\)00397-4](https://doi.org/10.1016/S0021-9150(99)00397-4)
17. Shelness GS, Sellers JA (2001) Very-low-density lipoprotein assembly and secretion. *Curr Opin Lipidol* 12(2):151–157. <https://doi.org/10.1097/00041433-200104000-00008>
18. Gorski J (1992) Muscle triglyceride-metabolism during exercise. *Can J Physiol Pharmacol* 70(1):123–131. <https://doi.org/10.1139/y92-019>
19. Herzer S, Meldner S, Grone HJ, Nordstrom V (2015) Fasting-induced lipolysis and hypothalamic insulin signaling are regulated by neuronal glucosylceramide synthase. *Diabetes* 64(10):3363–3376. <https://doi.org/10.2337/db14-1726>
20. Ahmadian M, Duncan RE, Jaworski K, Sarkadi-Nagy E, Sul HS (2007) Triacylglycerol metabolism in adipose tissue. *Futur Lipidol* 2(2):229–237. <https://doi.org/10.2217/17460875.2.2.229>
21. Spector AA (1975) Fatty acid binding to plasma albumin. *J Lipid Res* 16(3):165–179
22. van der Vusse GJ (2009) Albumin as fatty acid transporter. *Drug Metab Pharmacokinet* 24(4):300–307. <https://doi.org/10.2133/dmpk.24.300>
23. Corica F, Corsonello A, Ientile R et al (2006) Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. *J Am Coll Nutr* 25(3):210–215. <https://doi.org/10.1080/07315724.2006.10719534>
24. Guerrero-Romero F, Rodriguez-Moran M (2002) Low serum magnesium levels and metabolic syndrome. *Acta Diabetol* 39(4):209–213. <https://doi.org/10.1007/s005920200036>
25. Gueux E, Rayssiguier Y, Piot MC, Alcindor L (1984) Reduction of plasma lecithin-cholesterol acyltransferase activity by acute magnesium deficiency in the rat. *J Nutr* 114(8):1479–1483. <https://doi.org/10.1093/jn/114.8.1479>
26. Kurstjens S, van Diepen JA, Overmars-Bos C et al (2018) Magnesium deficiency prevents high-fat-diet-induced obesity in mice. *Diabetologia* 61(9):2030–2042. <https://doi.org/10.1007/s00125-018-4680-5>
27. Soininen P, Kangas AJ, Wurtz P et al (2009) High-throughput serum NMR metabolomics for cost-effective holistic studies on systemic metabolism. *Analyst* 134(9):1781–1785. <https://doi.org/10.1039/b910205a>
28. Netea MG, Joosten LAB, Li Y et al (2016) Understanding human immune function using the resources from the Human Functional Genomics Project. *Nat Med* 22(8):831–833. <https://doi.org/10.1038/nm.4140>
29. Matthews DR, Hosker JR, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28(7):412–419. <https://doi.org/10.1007/BF00280883>
30. Wurtz P, Havulinna AS, Soininen P et al (2015) Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. *Circulation* 131(9):774–785. <https://doi.org/10.1161/CIRCULATIONAHA.114.013116>
31. Kettunen J, Tukiainen T, Sarin AP et al (2012) Genome-wide association study identifies multiple loci influencing human serum metabolite levels. *Nat Genet* 44(3):269–276. <https://doi.org/10.1038/ng.1073>
32. Brereton MF, Iberl M, Shimomura K et al (2014) Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. *Diabetologia* 57:S93–S93
33. Girard CA, Wunderlich FT, Shimomura K et al (2009) Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. *J Clin Invest* 119(1):80–90. <https://doi.org/10.1172/JCI35772>
34. de Vries MA, van der Meulen N, van de Geijn GM et al (2017) Effect of a single dose of vitamin D3 on postprandial arterial stiffness and inflammation in vitamin D-deficient women. *J Clin Endocrinol Metab* 102(3):992–1000. <https://doi.org/10.1210/jc.2016-3394>
35. Mosteller RD (1987) Simplified calculation of body-surface area. *N Engl J Med* 317:1098–1098
36. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M (2006) Fatty acid signaling in the  $\beta$ -cell and insulin secretion. *Diabetes* 55(Suppl 2):S16–S23. <https://doi.org/10.2337/db06-S003>
37. Takaya J, Higashino H, Miyazaki R, Kobayashi Y (1998) Effects of insulin and insulin-like growth factor-1 on intracellular magnesium of platelets. *Exp Mol Pathol* 65(2):104–109. <https://doi.org/10.1006/exmp.1998.2232>
38. Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG (2000) Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. *Cell* 100(6):645–654. [https://doi.org/10.1016/S0092-8674\(00\)80701-1](https://doi.org/10.1016/S0092-8674(00)80701-1)
39. Flink EB, Shane SR, Scobbo RR, Blehschmidt NG, McDowell P (1979) Relationship of free fatty acids and magnesium in ethanol withdrawal in dogs. *Metabolism* 28(8):858–865. [https://doi.org/10.1016/0026-0495\(79\)90213-0](https://doi.org/10.1016/0026-0495(79)90213-0)
40. Zaloga GP, Willey S, Tomasic P, Chernow B (1987) Free fatty acids alter calcium binding: a cause for misinterpretation of serum calcium values and hypocalcemia in critical illness. *J Clin Endocrinol Metab* 64(5):1010–1014. <https://doi.org/10.1210/jcem-64-5-1010>
41. Jahnen-Dechent W, Ketteler M (2012) Magnesium basics. *Clin Kidney J* 5(Suppl 1):i3–i14. <https://doi.org/10.1093/ndtplus/sfr163>
42. Bodenhamer J, Bergstrom R, Brown D, Gabow P, Marx JA, Lowenstein SR (1992) Frequently nebulized beta-agonists for asthma: effects on serum electrolytes. *Ann Emerg Med* 21(11):1337–1342. [https://doi.org/10.1016/S0196-0644\(05\)81898-0](https://doi.org/10.1016/S0196-0644(05)81898-0)
43. Romani AM (2008) Magnesium homeostasis and alcohol consumption. *Magnes Res* 21(4):197–204
44. Ryzen E, Servis KL, Rude RK (1990) Effect of intravenous epinephrine on serum magnesium and free intracellular red blood cell magnesium concentrations measured by nuclear magnetic resonance. *J Am Coll Nutr* 9(2):114–119. <https://doi.org/10.1080/07315724.1990.10720359>
45. Bremme K, Eneroth P, Nordstrom L, Nilsson B (1986) Effects of infusion of the beta-adrenoceptor agonist terbutaline on serum magnesium in pregnant women. *Magnesium* 5(2):85–94
46. Stewart WK, Fleming LW (1973) Features of a successful therapeutic fast of 382 days duration. *Postgrad Med J* 49(569):203–209. <https://doi.org/10.1136/pgmj.49.569.203>
47. Ayuk J, Gittoes NJ (2014) Contemporary view of the clinical relevance of magnesium homeostasis. *Ann Clin Biochem* 51(2):179–188. <https://doi.org/10.1177/0004563213517628>
48. Kao LC, Cheng MH, Warburton D (1984) Triglycerides, free fatty acids, free fatty acids/albumin molar ratio, and cholesterol levels in serum of neonates receiving long-term lipid infusions: controlled trial of continuous and intermittent regimens. *J Pediatr* 104(3):429–435. [https://doi.org/10.1016/S0022-3476\(84\)81111-7](https://doi.org/10.1016/S0022-3476(84)81111-7)
49. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM (1996) Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. *Am J Obstet Gynecol* 174(3):975–982. [https://doi.org/10.1016/S0002-9378\(96\)70336-8](https://doi.org/10.1016/S0002-9378(96)70336-8)
50. Desideri-Vaillant V, Bordier L, Gidenne S et al (2004) Value of non-esterified fatty acids quantification in diabetes. *Ann Biol Clin (Paris)* 62(2):177–182 [article in French]
51. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW (2000) Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). *Eur J Clin Invest* 30(1):45–52. <https://doi.org/10.1046/j.1365-2362.2000.00597.x>